A new study suggests a drug could support the brain’s own repair systems after traumatic injury, potentially addressing a major treatment gap.
The compound, known as CMX-2043, appears to increase levels of antioxidant enzymes – proteins that help clear harmful molecules from the brain following trauma.
There are currently no FDA-approved drugs that directly repair or prevent brain damage after traumatic brain injury (TBI), which affects millions of people annually.
Researchers from the University of Georgia tested CMX-2043 in a swine model and found the drug appeared to enhance the brain’s natural defence mechanisms. CMX-2043 is based on a natural antioxidant – a type of molecule that protects cells from damage caused by unstable molecules known as free radicals.
“What really caught our attention was how CMX-2043 seemed to jumpstart the brain’s natural defences,” said Franklin West, senior author of the study and professor in the College of Agricultural and Environmental Sciences. “We saw clear increases in enzymes. Basically, they’re the cleanup crew that rushes in after an injury. That tells us the therapy might really be stepping in where the brain needs support most.”
TBI sets off widespread inflammation and cellular damage. According to the US Centers for Disease Control and Prevention, tens of thousands of people in the US die each year due to TBI-related injuries.
Initially studied for heart injury, CMX-2043 is now being explored for its potential to limit long-term brain damage after TBI. This study is the first to observe brain-specific enzyme activity linked to the drug in a swine model, suggesting a possible link between antioxidant activity and recovery in the brain.
“When the brain’s antioxidant defences were stronger, the damage we saw on MRI scans was lower. That’s a big deal. It means we might be able to help the brain heal better by boosting its own repair systems,” said co-author Erin Kaiser, assistant professor in the College of Agricultural and Environmental Sciences.
Lead author Hea Jin Park, associate professor in the College of Family and Consumer Sciences, added:
“What surprised us was that CMX-2043 didn’t directly cause the changes we saw in antioxidant enzyme levels. Those shifts were actually the body’s own reaction to the injury, but CMX-2043 may be helping to strengthen that built-in defence system.”
The team plans to use non-invasive tools such as magnetic resonance spectroscopy to track the drug’s impact in real time and assess its potential in human TBI treatment.
West, who co-founded the university’s Regenerative Bioscience Center, is collaborating with Erin Kaiser, Steven Stice, and Jarrod Call on the development of new TBI therapies.
“The early data really points to something promising: that boosting the brain’s own cleanup crew could help tilt the odds toward recovery after trauma,” West said.
